CLINICAL TRIALS

   research room at PHA's 2008 Conference
 

As the breadth of PH research expands, PHA is committed to keeping its members informed about ongoing clinical research pertaining to evaluation and treatment of pulmonary hypertension. One mechanism to achieve this is to provide institutions and other research sponsors who are conducting multi-center clinical trials with an opportunity to describe relevant studies.

PH Clinical Trials

Trial Name: A multi-center, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added-on to treprostinil, inhaled (Tyvaso) in subjects with pulmonary arterial hypertension
Sponsoring Institution: Lung Biotechnology Inc. (subsidiary of United Therapeutics)
Posted April 19, 2014
Read More

Trial Name: Targeting the Right Ventricle in Pulmonary Hypertension
Sponsoring Institution: University of Pennsylvania
Posted February 21, 2014
Read More

Trial Name: Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects wth Pulmonary Arterial Hypertension
Sponsoring Institution: United Theraputics Corporation
Posted August 27, 2013
Read More

Trial Name: Riociguat in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (EAS)
Sponsoring Institution:
Bayer Healthcare Pharmaceuticals
Posted July 3, 2013
Read more

Trial Name: PAHTCH - Pulmonary Arterial Hypertension Treatment with Carvedilol for Heart Failure
Sponsoring Institution: National Institutes of Health - The Cleveland Clinic
Posted March 27, 2013
Read more

Trial Name: Clinical Investigation of a Daily Walking Program plus L-Arginine Supplementation for the Treatment of Pulmonary Arterial Hypertension
Sponsoring Institution: Pulmonary Hypertension Association - American Thoracic Society
Posted February 28, 2013
Read more

Trial Name: A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension
Sponsoring Institution: National Institutes of Health
Posted January 22, 2013
Read more

Trial Name: A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension
Sponsoring Institution: National Institutes of Health
Posted January 22, 2013
Read more

Trial Name: A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population with Pulmonary Arterial Hypertension
Sponsoring Institution: Eli Lilly and Company
Posted July 6, 2012
Read more

Trial Name: An open-label study to explore the impact of inhaled trepostinil sodium on ventilation perfusion matching when used for treatment of group 1 pulmonary arterial hypertension in patients with concomitant chronic obstructive pulmonary disease (COPD)
Sponsoring Institution: United Therapeutics
Posted April 13, 2012
Read more

Trial Name: Clinical Study with ACT-293987 in Patients with Pulmonary Arterial Hypertension
Sponsoring Institution:
Actelion Pharmaceuticals, LTD
Posted April 11, 2012
Read more

Trial Name: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (AMBITION)
Sponsoring Institution: GlaxoSmithKline and Gilead Sciences
Posted January 31, 2012
Read more

Trial Name: Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Sponsoring Institution:
Ikaria, Inc.
Posted January 4, 2012
Read more

Trial Name: Determining the Prevalence and Progression of Secondary Pulmonary Hypertension in Adult Patients with Sickle Cell Anemia
Sponsoring Institution:
National Heart, Lung, and Blood Institute (NHLBI)
Posted December 15, 2011
Read more

Trial Name:
A Study to Evaluate Efficacy and Safety of Oral Bay 63-2521 in Patients with CTEPH
Sponsoring Institution: Bayer HealthCare Pharmaceuticals
Posted May 11, 2011
Read more

Trial Name: A Study to Evaluate Efficacy and Safety of Oral Bay 63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Sponsoring Institution: Bayer HealthCare Pharmaceuticals
Posted May 3, 2011
Read more

Trial Name: A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Sponsoring Institution: National Institute of Allergy and Infectious Diseases (NIAID)
Posted December 16, 2010
Read more


PHA ONLINE UNIVERSITY

Read the Advances in PH journal, take free CME/CEU courses, access presentations from major PH conferences, locate a medical education event near you and more.

Visit PHA Online University

Email Updates

Stay informed about current research, events, and more.

Sign up

FacebookGoogle +TwitterLinkedInPinterestInstagramYouTubeBloggerFeedsPHAware Download our App

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
Webmaster@PHAssociation.org
    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2014 Pulmonary Hypertension Association. All Rights Reserved.

NORD

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.